RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation

Lynett Danks, Noriko Komatsu, Matteo M. Guerrini, Shinichiro Sawa, Marietta Armaka, George Kollias, Tomoki Nakashima, Hiroshi Takayanagi

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objective RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis. Methods RANKL was specifically deleted in T cells (Tnfsf11flox/Δ Lck-Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf11flox/Δ Col6a1-Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf11flox/Δ Col2a1-Cre). Erosive disease was induced using the collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro-CT. Results The inflammatory joint score during CAIA was equivalent in all mice regardless of cell-targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf11flox/Δ and the Tnfsf11flox/Δ Lck-Cre groups during CAIA; however, the Tnfsf11flox/Δ Col6a1-Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used. Conclusions The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies.

Original languageEnglish
Pages (from-to)1187-1195
Number of pages9
JournalAnnals of the Rheumatic Diseases
Volume75
Issue number6
DOIs
Publication statusPublished - Jun 1 2016
Externally publishedYes

Fingerprint

Osteoclasts
Fibroblasts
Experimental Arthritis
Erosion
Bone
Collagen
Joints
Inflammation
Bone and Bones
T-cells
Osteogenesis
Arthritis
T-Lymphocytes
Cartilage
Antibodies
Articular Cartilage
Histology
Chondrocytes
Rheumatoid Arthritis
Degradation

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. / Danks, Lynett; Komatsu, Noriko; Guerrini, Matteo M.; Sawa, Shinichiro; Armaka, Marietta; Kollias, George; Nakashima, Tomoki; Takayanagi, Hiroshi.

In: Annals of the Rheumatic Diseases, Vol. 75, No. 6, 01.06.2016, p. 1187-1195.

Research output: Contribution to journalArticle

Danks, L, Komatsu, N, Guerrini, MM, Sawa, S, Armaka, M, Kollias, G, Nakashima, T & Takayanagi, H 2016, 'RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation', Annals of the Rheumatic Diseases, vol. 75, no. 6, pp. 1187-1195. https://doi.org/10.1136/annrheumdis-2014-207137
Danks, Lynett ; Komatsu, Noriko ; Guerrini, Matteo M. ; Sawa, Shinichiro ; Armaka, Marietta ; Kollias, George ; Nakashima, Tomoki ; Takayanagi, Hiroshi. / RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. In: Annals of the Rheumatic Diseases. 2016 ; Vol. 75, No. 6. pp. 1187-1195.
@article{8089c61f8d0b45b98cb31cf62377edcc,
title = "RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation",
abstract = "Objective RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis. Methods RANKL was specifically deleted in T cells (Tnfsf11flox/Δ Lck-Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf11flox/Δ Col6a1-Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf11flox/Δ Col2a1-Cre). Erosive disease was induced using the collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro-CT. Results The inflammatory joint score during CAIA was equivalent in all mice regardless of cell-targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf11flox/Δ and the Tnfsf11flox/Δ Lck-Cre groups during CAIA; however, the Tnfsf11flox/Δ Col6a1-Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used. Conclusions The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies.",
author = "Lynett Danks and Noriko Komatsu and Guerrini, {Matteo M.} and Shinichiro Sawa and Marietta Armaka and George Kollias and Tomoki Nakashima and Hiroshi Takayanagi",
year = "2016",
month = "6",
day = "1",
doi = "10.1136/annrheumdis-2014-207137",
language = "English",
volume = "75",
pages = "1187--1195",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation

AU - Danks, Lynett

AU - Komatsu, Noriko

AU - Guerrini, Matteo M.

AU - Sawa, Shinichiro

AU - Armaka, Marietta

AU - Kollias, George

AU - Nakashima, Tomoki

AU - Takayanagi, Hiroshi

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis. Methods RANKL was specifically deleted in T cells (Tnfsf11flox/Δ Lck-Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf11flox/Δ Col6a1-Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf11flox/Δ Col2a1-Cre). Erosive disease was induced using the collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro-CT. Results The inflammatory joint score during CAIA was equivalent in all mice regardless of cell-targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf11flox/Δ and the Tnfsf11flox/Δ Lck-Cre groups during CAIA; however, the Tnfsf11flox/Δ Col6a1-Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used. Conclusions The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies.

AB - Objective RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis. Methods RANKL was specifically deleted in T cells (Tnfsf11flox/Δ Lck-Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf11flox/Δ Col6a1-Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf11flox/Δ Col2a1-Cre). Erosive disease was induced using the collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro-CT. Results The inflammatory joint score during CAIA was equivalent in all mice regardless of cell-targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf11flox/Δ and the Tnfsf11flox/Δ Lck-Cre groups during CAIA; however, the Tnfsf11flox/Δ Col6a1-Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used. Conclusions The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies.

UR - http://www.scopus.com/inward/record.url?scp=84971634562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971634562&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2014-207137

DO - 10.1136/annrheumdis-2014-207137

M3 - Article

C2 - 26025971

AN - SCOPUS:84971634562

VL - 75

SP - 1187

EP - 1195

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -